RecruitingCardiometabolic Disease

Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity

Eligible age

18–65 yrs

Accepts

All genders

Locations

5 states

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

The primary objective of this study is to assess the safety and tolerability of AMG 513 after single and multiple doses.

Sponsor: Amgen

✓ Participants in the study will be males and females 18 to 65 years of age at the time of signing the informed consent with a body mass index (BMI) of 30.0 kg/m\^2 to 40.0 kg/m\^2 for Part A and BMI of 27.0 kg/m\^2 to 40.0 kg/m\^2 for Part B.
✓ Females enrolled must be of non-childbearing potential.

✕ History and/or clinical evidence of diabetes mellitus, including hemoglobin A1c ≥ 6.5% and/or a fasting glucose of ≥ 126 mg/dL (7 mmol/L) at screening.
✕ Triglycerides ≥ 5.65 mmol/L (i.e., 500 mg/dL) at screening.

Anaheim · Lake Forest · Oxnard

Aventura · Jacksonville · Miami

Union City

Fargo

Austin

Source: ClinicalTrials.gov · NCT06585462 · last updated 2026-06-22